Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00535873 · ClinicalTrials.gov registry record · Phase 2
Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT00535873: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00535873 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 61 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00535873, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
Primary Objective: * To assess the activity of lenalidomide in patients with previously untreated chronic lymphocytic leukemia (CLL) age 65 and older. Secondary Objective: * To assess the tolerability of lenalidomide in patients with untreated CLL age 65 and older
Interventions
- DRUG Lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2007-10 |
| Est. Completion | 2013-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00535873
The ClinicalTrials.gov registry entry for NCT00535873 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lenalidomide is the first listed.
NCT00535873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00535873 about?
NCT00535873 is a clinical study titled "Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older". Primary Objective: * To assess the activity of lenalidomide in patients with previously untreated chronic lymphocytic leukemia (CLL) age 65 and older. Secondary Objective: * To assess the tolerability of lenalidomide in patients with untreated CLL age 65 and older
What is the current status of trial NCT00535873?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2007-10. Estimated completion is 2013-02.
What interventions are being tested in trial NCT00535873?
The interventions under investigation include: Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT00535873?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.